About Pfizer, Inc.
Pfizer, Inc. (PFE) is a Healthcare company in the Pharmaceutical Preparations industry with a market capitalisation of $162.9B. The stock trades at 37.62x trailing earnings and yields 6.02%.
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Market cap
- $162.9B
- P/E ratio
- 37.62
- EPS (TTM)
- $1.36
- Revenue (TTM)
- $62.6B
- Free cash flow
- $9.1B
- Profit margin
- 12.4%
- Dividend yield
- 6.02%
- Shares outstanding
- 5.7B
Financial health: Weak4.4/10
3 strengths, 4 concerns. Weakest points: net debt vs cash flow, return on equity, revenue growth and 1 more.
- Debt to equity: 0.75 (Watch, benchmark < 0.5) — Debt of 0.75x equity is moderate against the 0.5x benchmark. It has deteriorated over the last 4 years.
- Net debt vs cash flow: 6.0y (Concern, benchmark < 4 years) — Net debt of $54.3B is 6.0x annual free cash flow — about 6 years of cash flow to repay.
- Current ratio: 1.16 (Watch, benchmark > 1.5) — Short-term assets cover 1.16x short-term liabilities, against Graham's 1.5x floor. It has been broadly flat over the last 4 years.
- Return on equity: 9.0% (Concern, benchmark > 15%) — Earns 9.0% on shareholder equity, well short of the > 15% mark.
- Gross margin: 73.2% (Strong, benchmark > 40%) — Keeps 73.2% of revenue after the direct cost of sales, comfortably past the > 40% mark.
- Net margin: 12.4% (Strong, benchmark > 10%) — Turns 12.4% of revenue into profit, comfortably past the > 10% mark.
- Free cash flow: $9.1B (Strong, benchmark positive) — Generated $9.1B of free cash flow after capital spending. It has deteriorated over the last 4 years.
- Revenue growth: -1.7% (Concern, benchmark > 10%) — Revenue changed -1.7% year on year, well short of the > 10% mark.
- Earnings growth: -3.2% (Concern, benchmark > 10%) — Earnings changed -3.2% year on year, well short of the > 10% mark.